LGL Group (NYSEAMERICAN:LGL) Stock Crosses Above 200 Day Moving Average – What’s Next?

LGL Group, Inc. (The) (NYSEAMERICAN:LGL)’s share price passed above its two hundred day moving average during trading on Thursday . The stock has a two hundred day moving average of $6.48 and traded as high as $7.38. LGL Group shares last traded at $7.26, with a volume of 2,083 shares changing hands.

LGL Group Price Performance

The firm has a market cap of $46.95 million, a P/E ratio of 42.30 and a beta of 0.31. The firm’s 50-day moving average price is $7.12 and its 200 day moving average price is $6.48.

Insider Buying and Selling

In other LGL Group news, major shareholder Mario J. Gabelli bought 95,387 shares of the stock in a transaction on Tuesday, December 30th. The shares were bought at an average price of $4.75 per share, with a total value of $453,088.25. Following the purchase, the insider directly owned 572,324 shares in the company, valued at $2,718,539. The trade was a 20.00% increase in their position. The acquisition was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Insiders own 18.90% of the company’s stock.

Institutional Trading of LGL Group

A hedge fund recently bought a new stake in LGL Group stock. Citadel Advisors LLC purchased a new position in LGL Group, Inc. (The) (NYSEAMERICAN:LGL) in the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor purchased 13,515 shares of the industrial products company’s stock, valued at approximately $90,000. Citadel Advisors LLC owned approximately 0.25% of LGL Group at the end of the most recent reporting period. 30.28% of the stock is currently owned by hedge funds and other institutional investors.

LGL Group Company Profile

LGL Group Inc is a United States–based company specializing in the development and commercialization of digital pathology and molecular imaging systems for research and clinical laboratories. The company’s core focus lies in enabling high-resolution visualization and quantitative analysis of tissue samples, helping scientists and pathologists accelerate biomarker discovery and diagnostic workflows. LGL Group’s platform combines advanced optics, automated slide scanning and image analysis software to deliver end-to-end solutions tailored to oncology, immunology and neuroscience research.

The company’s flagship offerings include whole-slide scanners capable of rapid, high-throughput scanning at resolutions suited for detailed morphometric and fluorescence studies.